Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$1.23
−$0.07 · -5.38%
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Previous close
$1.23
−$0.07 · -5.38%
Regular session · ET · Market data may be delayed.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Day range
Current $1.23
52-week range
Current $1.23
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
43
Mixed
Risk
51
Elevated Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Day range
Current $1.23
52-week range
Current $1.23
Operating income
Net income
| Metric (CAD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 62.27K CAD |
| Cost of goods sold | — | — | 187.38K CAD | 162.23K CAD | 174.26K CAD |
| Gross profit | — | — | −187.38K CAD | −162.23K CAD | −112K CAD |
| Research and development | 14.02M CAD | 14.01M CAD | 10.73M CAD | 13.99M CAD | 8.59M CAD |
| Selling, general, and administrative | 20.2M CAD | 25.89M CAD | 11.55M CAD | 16.34M CAD | 21.86M CAD |
| Operating expenses | 34.32M CAD | 40.28M CAD | 22.29M CAD | 30.33M CAD | 30.46M CAD |
| Interest income | 726.4K CAD | 1.19M CAD | 2.04M CAD | 1.24M CAD | 106K CAD |
| Depreciation and amortization | 101.98K CAD | 373.11K CAD | 248.36K CAD | 219.91K CAD | 220.42K CAD |
| Operating income | −34.32M CAD | −40.28M CAD | −22.47M CAD | −30.49M CAD | −30.57M CAD |
| Net income | −33.82M CAD | −36.68M CAD | −21.22M CAD | −22.82M CAD | −25.01M CAD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.00
550.41% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
